An overlooked opportunity for Israel and Saudi Arabia

Normalization between Israel and Saudi Arabia could be significantly bolstered by cooperation in biotechnology, offering a durable foundation beyond security and economic transformation. While the Palestinian issue remains a political constraint, the U.S. proposal to link civilian nuclear cooperation with Saudi Arabia to normalization with Israel could provide Crown Prince Mohammed bin Salman with a "Saudi Arabia first" framework to present the agreement to his public.

• Saudi Arabia's Vision 2030 aims to establish the kingdom as a global biotechnology hub, but it lacks the necessary capabilities, technology, and experienced human capital.
• Israel, a leader in biomedical discoveries, struggles to translate its innovations into globally competitive pharmaceutical companies capable of late-stage clinical development and commercialization.
• A joint framework could leverage Israel's early-stage discovery and development expertise with Saudi Arabia's scale, investment capacity, and clinical research infrastructure, creating a regional drug-development ecosystem.
• This collaboration would allow Saudi Arabia to build practical life sciences capabilities and Israel to access the resources needed to advance promising treatments into global medicines and companies, fostering a lasting mutual interest in preserving normalization.